INDEX

action preservation 13.136
administrative enforcement 1.34, 8.15, 12.18–12.55
lack of cross-regional co-operation 12.54–12.55
local authorities 12.19–12.22, 12.53
oral hearings 12.35–12.36
passing off cases 12.20–12.21
patent infringement procedures 12.23–12.50
statistical data 12.42–12.50
aesthetic feeling (designs) 20.08
agents 1.32, 9.05–9.06
Ajinomoto v Changchun Dabe (pending appeal) 4.54
all elements rule 15.22–15.23
alternative dispute resolution (ADR) 21.43–21.45
see also arbitration and mediation
animal and plant patents 3.15–3.16, 4.40–4.47, 21.18, 21.61
Animal Husbandry Act (PRC) 3.05, 4.17
antibody patents 4.70–4.89
Anti-Monopoly Commission 17.10, 17.24
Anti-Monopoly Law (AML) 17.01–17.106
administrative power, abuse of 17.81–17.83
case law 17.37–17.38, 17.41–17.42, 17.53–17.58
compulsory licensing 1.16
definitions 17.15–17.27
dominant market position, abuse of 17.43–17.58
enforcement see Anti-Monopoly Law (AML), enforcement of exemptions to prohibited agreements 17.33–17.36
history of 17.02
horizontal monopoly agreements 17.28–17.38, 17.99
IP rights, abuse of 17.59–17.69
merger control 17.14, 17.70–17.80
related legislation and regulations 17.03–17.09
scope of applicability 17.15–17.83
SEP holder liability under 18.49–18.56
structure of authorities 17.10–17.14
vertical agreements 17.39–17.42
Anti-Monopoly Law (AML), enforcement of 17.84–17.105
administrative enforcement 17.86
Anti-Monopoly Law Enforcement Authorities (AMEAs) 17.11, 17.85, 17.88
leniency 17.87–17.88
private actions in Chinese courts 17.96–17.105
remedies 17.84, 17.105
sanctions 17.84, 17.89–17.93
whistleblowing 17.86
Anti-Unfair Competition Law 17.04, 18.52
apparatus claims 6.54–6.59
appeals 9.48, 9.73, 13.23, 13.78–13.88
applications see patent application procedure; individual types of applications
arbitration 2.61, 7.48
Bai Wangting v Tianxiang Co. (SPC) 15.18–15.19
Baiyun Airport case (Guangzhou Intermediate People’s Court) 18.45
Bang & Olufsen v To Huk Chung (HKC) 22.43
Basic People’s Courts 12.09–12.13, 13.14
Beijing Patent Trial Opinions 8.47–8.48
Beijing Xichuang Advertisement Co., Ltd. v Beijing Haitian Training School (Haidian District Court) 18.24
biological material 4.18, 10.10

455

Stefan Luginbuehl and Peter Ganea - 9781781954843
Downloaded from Elgar Online at 04/24/2019 09:47:00PM via free access
INDEX

biotechnological, chemical and pharmaceutical inventions 4.01–5.20
antibody patents 4.70–4.89
chemical compositions, and support requirement 5.10, 5.15
chemical compounds 4.56–4.66, 5.01–5.09, 5.18
chemical processes, and support requirements 5.11
crystalline of compounds 4.67–4.69
data exclusivity and 4.92–4.93
industrial applicability 4.07–4.15
market exclusivity, period for new drugs 4.94–4.99
measuring methods 5.16
non-patentable inventions 4.16–4.47
patentable subject matter 4.05–4.47
stem cells 4.19, 4.42–4.43
support requirements and experimental data 4.12, 4.77, 4.81, 4.82–4.83, 5.01–5.20
support-from-description 4.48–4.89
Swiss-type claims 4.32–4.39
Bolar exemption 1.15, 4.90, 8.01, 8.48, 8.53–8.54
burden of proof 16.16–16.21
business methods 3.08, 6.31
business secrets 2.29, 13.31, 13.44

Canon v Green Cartridge (HKLRD) 22.39, 22.54
cartels 17.01, 17.18, 17.35, 21.51, 21.53
Catnic Components Ltd and Another v Hill & Smith Ltd (UKHL) 22.29
chemical inventions see biotechnological, chemical and pharmaceutical inventions
case-and-desist orders 17.91, 17.105
central definition theory 15.06
cessation of infringement 12.41, 13.52–13.59
chemical inventions see biotechnological, chemical and pharmaceutical inventions
China Holding Company (CHC) 7.38
Chinese language 2.60
China’s patent policy, overview 1.01–1.39, 2.36–2.46
see also National Intellectual Property Strategy (NIPS)
indigenous innovation policy 1.20–1.32
see also individual policies and guidelines
Chinese Patent Act (PRC)
proposed improvements 1.37, 13.176–13.184, 14.57–14.58
revisions to 1.07–1.19, 2.43, 4.02, 8.01–8.05, 12.18, 13.175–13.184, 14.55–14.58
Chinese Patent Act (PRC), exceptions to 3.02–3.17, 8.01–8.63
Bolar exemption 1.15, 4.90, 8.01, 8.48, 8.53–8.54
case law 8.06–8.08
exhaustion of rights 1.17, 8.17–8.21, 16.06–16.15, 21.14
prior art defence 8.36, 8.58–8.62
prior use defence 8.22–8.36, 14.48–14.51
regulatory approval 8.52–8.57
scientific research and experiments 8.41–8.51
statutory limitations 8.09–8.16
temporary transit 8.37–8.40
Chinese Taipei (Taiwan), patent system 21.01–21.62
adoption of international exhaustion 21.14
alternative dispute resolution and border measures 21.43–21.45
animal and plant patents 21.18, 21.61
Board of Appeal 21.28–21.29
civil infringement proceedings 21.33–21.48
compulsory licensing and government use 21.15–21.17
Conflict of Law Act 21.41–21.42
damages 21.08–21.09
design patents 21.11–21.13
enforcement 21.30–21.48
Executive Yuan 21.18
expert verification 21.37, 21.54
false patent marking 21.46
fees 21.20–21.21
file-wrapper estoppel 21.27
FRAND (fair, reasonable and non-discriminatory) 21.54
INDEX

infringement, definition 21.34
infringement remedies 21.07–21.09
Intellectual Property Dispute Arbitration Research Committee 21.43
international jurisdiction 21.41
IP Adjudication Act 21.31
IP Court 21.02, 21.29, 21.31–21.32
Judicial Yuan 21.31, 21.37
language requirements for applications 21.22
Legislative Yuan 21.31
licensing agreements 21.49–21.56
Ministry of Economic Affairs (MOEA) 21.29, 21.38
notarization of evidence 9.61
patent agents 9.05
patent infringement jurisdiction 13.14
patent invalidation 21.10
patent pools 21.53–21.56
patent prosecution 21.26–21.29
Patent Search Center 21.25
pharmaceutical and agrochemical inventions 21.19
refusal to license and warning letters 21.49–21.52
remedies 21.38
revocation 21.29
Six Newly Developed Industries 21.04
Taiwan Fair Trade Act (TFTA) 21.46, 21.49–21.50
Taiwanese Fair Trade Commission (TFTC) 21.49–21.56
third-party observations 9.30
Chinese Tort Act (PRC) 13.51, 13.75–13.76, 16.29
Chint v Schneider (Zhejiang High People’s Court) 13.33, 13.64–13.65, 19.05, 19.32
CIELA (database) 1.34, 8.08, 8.16, 8.20, 8.35, 8.50, 8.61–8.62
civil proceedings, patent infringement 13.20–13.32
claim as a whole 6.38–6.40
claim interpretation by court system 15.01–15.43
all elements rule 15.22–15.23
basis of claim interpretation 15.09–15.13
dedication rule 15.24–15.26
estoppel rule 15.27–15.32
intrinsic vs. extrinsic evidence 15.15–15.21
means-plus-function claims 15.40–15.42
patent litigation practices 15.01–15.04
principles of claim interpretation 15.05–15.08
product-by-process claims 15.33–15.39
see also court system; judicial enforcement
collegiate panels 9.43, 9.68
Commerce, Ministry of (MOFCOM) 2.12, 2.18–2.23, 17.11–17.12, 17.68, 17.70–17.80
common law 2.60, 8.06, 12.11, 22.02
compensation see damages
compulsory licences and licensing 1.16, 13.53
counterfeit patents see patent counterfeiting
counterfeit products 12.02, 12.42
countrastsuits 13.48, 13.111
court system
employee invention dispute resolution 7.46
foreign companies and 1.34
forum shopping and 1.34
costs of litigation see litigation costs
counterfeit patents see patent counterfeiting
counterfeit products 12.02, 12.42
countrastsuits 13.48, 13.111
court system
employee invention dispute resolution 7.46
foreign companies and 1.34
forum shopping and 1.34

457
Stefan Luginbuehl and Peter Ganea - 9781781954843
Downloaded from Elgar Online at 04/24/2019 09:47:00PM
via free access
INDEX

invention patents vs. utility models 19.30
jurisdiction 12.07–12.13, 13.14
lack of binding precedent system in 8.06
private AML actions 17.96–17.105
Cross-Strait Agreement on Intellectual Property Rights Protection and Cooperation (IPR Agreement) 21.57–21.62
see also Chinese Taipei (Taiwan), patent system
Cubist decision (SPC) 4.36, 4.39
customs protection
detention 13.154–13.159
patent infringement litigation and 13.146–13.163
patent registration 13.150–13.153
customs representatives, for foreign parties 13.161
damages 1.18–1.19, 1.34, 2.29, 13.60–13.74, 13.133
data exclusivity 4.92–4.93
declarations of non-infringement 4.101–4.102, 13.18, 18.61, 22.22, 22.60–22.64
dedication rule 15.24–15.26
design, definition 20.05
design patents 20.01–20.77
administrative infringement procedures 12.25
basic design 20.25
best practices 2.53–2.54
brief explanation 20.21, 20.23, 20.28, 20.36, 20.61
design, definition 20.05
drawings/photographs, defects of 20.20
enforcement issues see design patents, enforcement of
evaluation reports 12.25, 14.63
legal framework 20.05–20.18
multiple designs 20.24–20.27
non-patentable designs 20.10
non-patentable subject matter 20.11
normal consumer standard 20.30–20.31
as not regarded as technology rights 2.11
preliminary examination 20.19–20.28
preliminary injunctions 13.127
priority period 20.28
requirements for 20.12–20.18, 20.29–20.45
significant difference 20.16, 20.39–20.45
see also drawings; photographs
design patents, enforcement of 20.46–20.77
deviating designs 20.56–20.58
evaluation reports 20.59–20.65
invisible products 20.53–20.55
normal consumer standard 20.46–20.52
prior art defence 20.66–20.73
products with several components 20.74–20.77
destruction, as remedy 13.77, 21.38
detention, in customs protection 13.154–13.159
diagnostic methods see medical diagnostic methods
disclosure 2.55, 3.28, 3.29, 7.13
discovery order Macau SAR 23.47
discriminatory pricing 18.49
dispute resolution 7.44–7.48, 8.15, 13.13
divisional applications 9.07–9.10, 20.27
DNA, and patents 4.74–4.75, 5.20
Doha Declaration on the TRIPs Agreement and Public Health 1.16
dominant market position, abuse of 17.43–17.58
double patenting, prohibition on 1.12, 3.43–3.52, 9.11–9.14
amendments of application 9.12–9.13
conflicting patent applications vs. 3.45–3.46
consequences of 3.52
exceptions to 3.47–3.51
drawings
claim interpretation and 15.06, 15.08, 15.15–15.16, 15.20, 15.24
conflicting applications and 3.46
defects of 20.20
formality examination and 9.28
means–plus-function claims and 15.40
prior use and 8.23, 8.31
see also design patents
Drug Administration Act (PRC) 4.36, 4.92, 4.96, 4.100–4.102
INDEX

eBay Inc. v MercExchange (USSC) 13.57, 18.44
eclectic interpretation theory 15.06, 15.08
embodiments 4.39, 4.48, 6.20, 14.51, 15.21, 16.37
embryonic stem cells 4.19, 4.42–4.43
employee inventions 7.01–7.52
definition 7.04–7.07
dispute resolution 7.44–7.48
within groups or holdings 7.37–7.43
legal framework 7.02–7.10
proposed improvements 7.49–7.52
rights and duties of employees 7.15–7.33
rights and duties of employers 7.12–7.14, 7.52
service-invention, definition 7.08–7.10
university inventions 7.34–7.36
employees, and confidentiality 2.56
employment agreements 7.52
enforcement
claim interpretation see claim interpretation by court system
dual system of see enforcement, dual system of
infringement and invalidity proceedings see infringement and invalidity proceedings
patent infringement procedures see patent infringement litigation and remedies
process patent-related aspects of infringement see process patent infringement
remedies see patent infringement litigation and remedies
enforcement, dual system of 12.01–12.58
administrative 1.34, 8.15, 12.18–12.55
see also administrative enforcement judicial 12.06–12.17
under NIPS 1.33–1.34
equivalents/equivalence doctrine 8.60, 13.130, 14.39, 14.49, 15.06, 15.14, 15.24–15.25, 15.27, 15.34, 21.36, 22.30
essential facilities doctrine 18.55–18.56, 18.63
European Patent Convention (EPC) 3.40, 15.06, 22.04, 22.28, 22.55
European Patent Office (EPO)
experimental data/evidence 4.81
file-wrapper estoppel 21.27
patents granted to Chinese applicants 1.26
technical solution 6.12
European Telecommunications Standards Institute (ETSI) 18.08
evidence
administrative infringement procedures 12.27–12.32
intrinsic vs. extrinsic evidence 15.15–15.21
patent infringement litigation and
preservation of 13.137–13.142
excessive pricing 18.53
exclusions from patentability 3.03
international exhaustion principle, parallel imports
exhibitions, and patent rights protection 3.32–3.34, 13.164–13.174
experimental data/evidence
antibody patents and 4.77
for biochemical material 4.12
under EPO system 4.81
post-filing of 4.82–4.83, 5.12–5.13
support requirements and 5.01–5.20
exports see imports and exports
fees
attorneys 13.117–13.118
customs registration 13.151
extension of application time limits 9.32
invalidation procedure 9.74
PCT-CN applications 10.03, 10.06, 10.37–10.38

459

Stefan Luginbuehl and Peter Ganea - 9781781954843
Downloaded from Elgar Online at 04/24/2019 09:47:00PM
via free access
INDEX

translation of documents 9.60
fines 1.32, 13.135, 17.89, 17.91–17.93, 23.40–23.42, 23.45
first-to-file principle 3.33, 3.43–3.44, 9.01–9.02
first-to-invent principle 9.02
force majeure 9.78–9.79
foreign direct investment (FDI) 1.03, 1.39, 2.13
Foreign Investment Catalogue 2.13
foreign language applications see translation of foreign documents
forum shopping 1.34
FRAND (fair, reasonable and non-discriminatory) terms, definition 18.03–18.04, 21.54
see also RAND; standard-essential patents (SEPs), and injunctive relief
Füllplastverfahren decision (BGH) 16.13
functional features 4.52, 15.40

General Administration of Quality Supervision, Inspection and Quarantine (AQSIQ) 17.82
generic drugs 4.98, 8.53–8.54
genes 4.11–4.12, 4.22
genetic resources 1.14, 3.05, 4.17–4.18
Germany, patent system 1.26, 13.117, 15.43, 16.08, 18.61, 21.17, 21.30, 21.32, 21.35
bifurcated patent litigation system 14.08, 14.55, 19.31
employee inventions 7.01, 7.12, 7.28, 7.42
exhaustion of rights 16.13
indirect infringement 16.26
PPH bilateral programmes 1.24
prior art 3.26
superfluous definition doctrine 15.23
university inventions 7.35
utility models 1.28, 3.27, 19.02
grace period 3.32–3.34
graphical user interfaces (GUI) 20.11, 21.12

He Guoying v Dazu County Guo HaoMachinery Factory (Beijing Intermediate People's Court) 8.35
Herfindahl-Hirschman Index 17.80
High and New Technology Enterprises (HNTE) programme 2.42
High People's Courts 7.24, 7.26, 7.30, 9.48, 9.73, 12.09–12.13, 13.14, 13.31, 13.79, 15.02, 16.15
see also individual cases
Honeywell International Inc. v Hamilton Sundstrand Co. (USCA) 15.31–15.32
Hong Kong SAR, patent system 22.01–22.70
Anton Piller Order 22.35
challenges to patent validity 22.48–22.55
court jurisdictions 22.17–22.18, 22.26
declarations of non-infringement 22.61–22.64
dual official languages in 22.19–22.21
foreign parent companies as joint tortfeasors 22.40
granting of patent rights 22.07–22.16
High Court 22.15, 22.17, 22.26, 22.48, 22.69
infringement proceedings 22.23–22.47
notarization of evidence 9.61
patent agents 9.05
patent infringement jurisdiction 13.14
patent litigation practices 22.17–22.64
proposed improvements 22.65–22.69
short-term patents 22.14, 22.67
standard patents 22.09–22.12
summary judgment 22.37
transit of goods 22.43
unjustified threats actions 22.56–22.60
horizontal boycotts 17.32
horizontal monopoly agreements 17.28–17.38, 17.99
Huawei v IDC (Shenzhen Intermediate People's Court) 18.20, 18.56
Human embryos 4.19, 4.42–4.43
imports and exports 2.14–2.23, 8.19, 13.70–13.71
see also customs protection
Improver Corp v Raymond Industrial Ltd (HKC) 22.29
indigenous innovation policy 1.20–1.32
financial incentives 1.25
NIPS provisions 1.20–1.21
PCT system and 1.23
indirect infringement 16.24–16.35

460
Stefan Luginbuehl and Peter Ganea - 9781781954843
Downloaded from Elgar Online at 04/24/2019 09:47:00PM
via free access
INDEX

industrial applicability 3.09, 3.42, 4.07–4.15
infringement
  administrative enforcement of 12.23–12.50
  indirect infringement 16.24–16.35
  invalidity proceedings see infringement and invalidity proceedings
litigation and remedies see patent
  infringement litigation and remedies
process patent infringement see process patent infringement
statutory limitations 8.09–8.16
TRIPs Agreement and 8.01
infringement and invalidity proceedings 14.01–14.65
  claim amendments 14.31–14.32
  counterclaims concerning malicious assertion of invalidity 14.52–14.54
  differing claim interpretations 14.36–14.38
  harmonisation of claim interpretation 14.42–14.44
  preliminary injunctions 14.33–14.34
  proposed improvements 14.55–14.65
  revocation procedures 14.01–14.06, 14.45–14.46
  separated vs. combined systems 14.07–14.08
  suspension of infringement procedure 14.09–14.30
see also Patent Reexamination Board (PRB)
injunctions 8.12, 12.20, 13.52–13.58
see also preliminary injunctions
Institute of Electrical and Electronics Engineers (IEEE) 18.08, 18.29
intellectual activities and laws of nature 3.08, 6.15–6.34
intellectual property (IP) rights, abuse of 17.59–17.69
interested parties, definition 12.23, 20.60
Interim Measures for the Administration of Human Genetic Resources 3.05
see also individual cases
international applications see PCT-CN applications
International Bureau 10.15
International Classification for Industrial Designs 20.22
international exhaustion principle 1.17, 8.18–8.19, 21.14
see also exhaustion of rights; parallel imports
international phase see PCT-CN applications
International Preliminary Examination (PCT) 10.43
International Search Authority (ISA) 10.42
International Telecommunication Union (ITU) 18.29
Interpretation of the Supreme People’s Court on Several Issues concerning the Application of Law in the Trial of Patent Infringement Dispute Cases (2010) 1.07, 13.08
invalidation procedure (PRB) 9.49–9.74, 19.31
see also infringement and invalidity proceedings
amendments 9.63–9.67
collegiate examination 9.57–9.74
examination method 9.68–9.71
formality examination 9.52–9.56, 20.01
request for 9.49–9.51
termination of 9.72–9.74
invention, definition 3.01, 4.05
inventive step/inventiveness 3.35–3.41
antibody patents 4.78
claim as a whole 6.38–6.40
criteria for 3.41, 9.28
definition 3.35
invention patents 19.15–19.17
notable progress 3.40
software-related inventions and 6.35–6.53
three-steps approach 3.38, 6.32
utility models 3.36–3.38, 19.15–19.17
IP Five Year Plan (SIPO) 12.03, 12.22

Stefan Luginbuehl and Peter Ganea - 9781781954843
Downloaded from Elgar Online at 04/24/2019 09:47:00PM via free access
INDEX

Japan, patent system 1.24, 2.37, 8.51, 10.03, 16.08, 19.02, 21.17, 21.24–21.25, 21.32

Johnson & Johnson v Rainbow Medical (Shanghai High People's Court) 17.36, 17.42

joint venture (JV) 2.03, 2.13, 2.37–2.38, 2.52

Ju Aijun v Gubeichun Co. (Shandong High People's Court) 16.08

judicial enforcement 12.06–12.17
court system and jurisdiction 12.07–12.13, 13.14
statistical data 12.14–12.17
see also claim interpretation by court system
junk patents 1.30, 3.35
jurisdiction
within Chinese court system 12.07–12.13, 13.14
of local authorities 12.53
patent infringement and 13.14–13.17
see also individual courts and patent systems

Kirin-Amgen v Hoechst Marion Roussel (UKHL) 22.30

KK Yakult Honsha v Yakudo Holdings Ltd (HKLRD) 22.39

know-how protection 2.05, 2.55–2.58, 16.02–16.03, 17.67, 17.69

labour contracts 7.07, 7.48
lack-of-support objection 4.53–4.54
language requirements for applications see translation of foreign documents

Lanzhou Xitaihua Industry and Trade Group and Lanzhou Hailande Pump Co. Ltd v Magnetic Advice Research Institute of Gansu Academy of Science (Gansu Intermediate People's Court) 17.38

Law of the People's Republic of China on Promoting the Transformation of Scientific and Technological Achievements 7.29

laws of nature see intellectual activities and laws of nature
liability
under AML 17.13, 18.49–18.56
for erroneously requested preliminary injunctions 13.133
dominant market position and 17.48
exemptions from damages 13.70–13.71, 13.74
indirect infringement and 16.26
joint liability 16.29–16.33
limited liability 12.28
warning letters and 13.73
litigation costs 13.99–13.118
local protectionism 1.34, 12.16, 12.51–12.52, 17.82
Locarno Agreement 20.22
Low Ban Chai, In Re (HKLRD) 22.26

Macau SAR, patent system 23.01–23.47
civil proceedings 23.46–23.47
criminal proceedings and fines 23.31–23.45
enforcement 23.27–23.47
exclusions from patentability 23.12–23.14
extension of Chinese patents 23.04, 23.06–23.10

granting of patent rights 23.01–23.10
Industrial Property Code (IPC) 23.01
inventive step/inventiveness, definition 23.17
Macau Customs (MC) 23.28–23.30
as nonparty to PCT 23.18
notarization of evidence 9.61
novelty 23.15
patent agents 9.05
patent infringement jurisdiction 13.14
patent registration 23.18–23.26
patentability requirements 23.11, 23.20–23.21
prior art, definition 23.15
provisional protection 23.25
substantive patent law 23.11–23.17
third-party observations 9.30
manufacturing substitutability 17.27
market power see Anti-Monopoly Law (AML); standard-essential patents (SEPs), and injunctive relief
Markush-type claim 5.02
means-plus-function claims 15.40–15.42, 16.37
Measures for the Examination and Approval of Entry and Exit and the Foreign Cooperative Research on the Application of Genetic Resources of Livestock and Poultry 3.05, 4.17
measuring methods 5.16
mediation 1.34, 12.36, 12.40, 13.30
medical diagnostic methods 3.09–3.14, 4.23–4.27, 4.32–4.39
medical treatment methods 3.09–3.14, 4.28–4.39
medicament, Swiss-type claim format for 4.32–4.39
mental activities see intellectual activities and laws of nature
merger control 17.14, 17.70–17.80
method patents see process patents
microorganisms, definition 4.44
Microsoft Co. v Motorola, Inc. (USCA) 18.29, 18.31
misuse 21.49
monopolistic agreement, definition 17.22–17.23
monopolistic conduct, definition 17.16
morality see social morality
mutagenesis 4.14–4.15, 4.75
naked Bolar exemption 8.01, 8.53
NanoWorld (HK) Ltd v Nano Biotechnology Holdings Ltd (HCA) 22.60
National Development and Reform Commission (NDRC) 17.01, 17.11–17.12, 17.21, 17.39–17.42, 17.95
National Intellectual Property Strategy (NIPS) 1.04–1.33
indigenous innovation policy 1.20–1.32
Patent Act revisions and improvements 1.07–1.19
patent rights enforcement 1.33–1.34
national interest 1.13–1.19, 2.15, 3.17, 3.20, 11.14
National Patent Development Strategy (2011–2020) (NPDS) 1.06, 1.20
National People's Congress (NPC)
IP Five Year Plan 12.03, 12.22
Standing Committee 13.06
national phase 4.49, 9.04
see also PCT-CN applications
National Standardization Committee 18.09
non-circumvention clauses 2.55
Non-Disclosure Agreements (NDAs) 2.55
non-obviousness see inventive step/inventiveness
non-patentable inventions 3.02–3.20, 4.16–4.47, 20.10–20.11
non-practicing entities (patent trolls) 1.31, 13.57
notable progress 3.40
notarization requirements 9.61, 12.26, 13.43, 13.50
novelty 3.22–3.34, 19.14
conflicting applications 3.30–3.31
definition 3.22
design patents 20.30–20.38
grace period 3.32–3.34
prior art 3.23–3.29
nuclear transmission devices 3.17
One-Blue 21.53–21.55
oral hearings 12.35–12.36, 13.29, 14.04
Orange-Book-Standard doctrine (BGH) 18.54, 18.61
O'Reilly v Morse (USSC) 6.19–6.20
parallel imports 8.19, 16.06, 16.12
see also exhaustion of rights
passing off (another person’s patent as one’s own) 12.20–12.21
Patent Act (Taiwan) 21.03–21.25
patent agencies 9.05–9.06
patent agents see agents
INDEX

patent application procedure 9.01–9.38
divisional applications 9.07–9.10
double patenting 9.11–9.14
examination after first Office Action 9.33–9.38
examination of formality and substance 9.28
filing procedure 9.03–9.06
first Office Action 9.23–9.32
first-to-file principle 9.01–9.02
preliminary examination 9.15–9.16
publication of patent applications 9.17–9.19
request for substantive examination and voluntary amendments 9.20–9.22
third-party observations and 9.29–9.30
patent assertion entities see patent trolls
Patent Cooperation Treaty (PCT) 1.08, 1.23
see also PCT-CN applications
patent counterfeiting 12.48–12.50, 12.53, 12.55
patent examination 9.01–9.91
inspection of files 9.85–9.91
invalidation see invalidation procedure (PRB)
patent application see patent application procedure
re-examination see re-examination procedure (PRB)
restoration of rights 9.77–9.79
suspension of procedures 9.80–9.84
time limits 9.75–9.79
Patent Examination Guidelines
inventiveness criteria 3.41
medicinal diagnostic methods, definition 3.10
medical treatment methods, definition 3.12, 3.14
public interest, definition 3.04
social morality, definition 3.04
see also individual guidelines
patent infringement litigation and remedies 13.01–13.184
amendments to claims 13.48
appeals 13.23, 13.78–13.88
civil proceedings 13.20–13.32
costs of litigation 13.99–13.118
countersuits 13.48
customs protection 13.146–13.163
future trends 13.175–13.184
initiation of proceedings 13.10–13.19
interim measures 13.119–13.145
laws and SPC provisions 13.07–13.09
legal framework 13.05–13.06
mediation 13.30
patent rights protection during exhibitions 13.164–13.174
preliminary injunctions 13.120–13.136
preservation of evidence 13.137–13.142
property preservation 13.143–13.145
protection during exhibitions 13.164–13.174
remedies 13.51–13.77
retrial 13.78, 13.89–13.98
Patent Prosecution Highway (PPH) 1.24, 21.24
Patent Reexamination Board (PRB)
on antibody disclosures 4.74
design patent assessment 20.41, 20.44
divisional applications and 9.09
on generalization of numeric ranges as support 5.15
invalidation procedure see invalidation procedure (PRB)
invalidity of Pfizer’s Viagra patent 5.03, 5.05
lack of support requirement 4.54
Notification of Examination on Request for Invalidation 9.69
Notification of Oral Proceedings 9.70
Notification of Re-Examination 9.44
Notification of Termination of Examination at Request for Invalidation 9.56
Notification to Make Rectification 9.55
re-examination procedure see re-examination procedure (PRB)
see also infringement and invalidity proceedings
patent trolls 1.31, 1.38
patentability definition 3.01
prerequisites for 3.01–3.52
INDEX

PCT-CN applications 10.01–10.44
amendments during international phase 10.41–10.44
ban on restoration of priority claims 10.13
Chinese corporate applicants 2.39
conflicting applications 3.30
early entry into national phase 10.14–10.15
excess claim fees 10.37–10.38
flowchart of procedures 10.16–10.20
International Preliminary Examination 10.43
International Search Report (ISR) 19.30
invention patent vs. utility model 10.04–10.05
inventions lacking unity 10.39–10.40
language requirements for 9.04, 21.22
post-filing experimental data 4.82
priority documents during international phase 10.12
requirements of 10.06–10.11
simultaneous application for patent/utility model, prohibition on 19.27
translation errors and issues 10.06, 10.29–10.36
voluntary amendments 10.21–10.28
see also Patent Cooperation Treaty (PCT)
peripheral definition theory 15.06
persons skilled in the art
eclectic interpretation and 15.08
examination of formality and substance and 9.28
plant cells and 4.46
support requirements and 5.07
technical solution 6.29
pharmaceutical patents 1.15, 8.46
see also biotechnological, chemical and pharmaceutical inventions
Philips v SK Kassetten (Hague DC) 18.41
see also design patents
piracy 12.02, 13.02, 13.13
plants see animal and plant patents
pledge and loan system 1.25
power of attorney 10.18, 12.24, 12.26, 13.24
practical applicability 3.42
see also injunctions
preservation of evidence see evidence
pre-trial hearings 13.27
Price Law 17.04
prior art 3.23–3.29
absolute novelty standard 3.24–3.27
definition 3.23
disclosure by publication 3.28
disclosure by use 3.29
invention patents and 19.19
utility models and 19.16, 19.18, 19.22
prior design see design patents
prior use defence 8.22–8.36, 13.43
priority claims, PCT-CN applications 10.12, 10.18
Probel v Parke Davis (HR) 22.42
procedural economy principle 9.37
process patents 6.54–6.59
infringement 15.33–15.39, 16.01–16.38
exhaustion of rights 16.06–16.15
indirect infringement 16.24–16.35
OBE v Kanghua decision and 16.36
product-by-process protection 16.22–16.23
reversal of burden of proof 16.16–16.21
product claims 9.28
product patents 6.54–6.59
product-by-process claims 15.33–15.39
products directly obtained from a patented process 16.22–16.23
Professor’s Privilege 7.35
property preservation 13.143–13.145
prostheses 3.13
public interest
abuse of IP rights and 17.64
dedication rule and 15.26
definition 3.04
infringement decisions and 13.55–13.59
non-patentable inventions and 3.03–3.04
publication, disclosure by 3.28
publication of patent applications 9.17–9.19, 19.23
INDEX

Qiao Chang Lin v Qingdao Ji’er Engineering Adhesives Co. Ltd (Shandong Intermediate People’s Court) 8.15
Qihoo 360 v Tencent QQ (Quangdong High People’s Court) 17.56–17.58, 17.101
Quanta Computers v LG (USSC) 16.13
RAND (reasonable and nondiscriminatory royalties, standards selection, and control of market power) terms,
definition 18.03, 18.09
see also FRAND, standard-essential patents (SEPs) and injunctive relief recycling 16.08
re-examination procedure (PRB) 9.39–9.48 amendments 9.40
collegiate examination 9.43–9.48 interlocutory examination 9.41–9.43 requests for 9.39–9.40 refusal to deal 17.47, 18.54 refusal to license 17.62, 17.65, 18.55, 18.63 refusal to trade 17.49 Regulation on the Protection of New Plant Varieties 3.16
Regulations on Technology Import and Export Administration 2.18, 2.27 relevant market, definition 17.24–17.27 remedies under AML 17.84, 17.105 in patent infringement litigation 13.51–13.77 remuneration, and employee inventions 7.20–7.27

Stefan Luginbuehl and Peter Ganea - 9781781954843
Downloaded from Elgar Online at 04/24/2019 09:47:00PM via free access
INDEX

simultaneous application (of invention patent and utility model) 1.12, 9.14, 19.24–19.27
SIPO see State Intellectual Property Office (SIPO)
skilled artisan see persons skilled in the art
SMEs (small and medium enterprises) 1.25, 1.37, 17.35
social morality 3.03–3.04, 4.19
software product claims, prohibition on 9.28
software-related inventions 6.01–6.60
assessment of inventive step 6.35–6.53
eligibility for patent protection 6.02–6.34
forms of claims 6.54–6.59
intellectual activities, rules and methods for 6.15–6.34
legal provisions 6.02–6.05
technical means and technical features 6.41–6.47
technical problems 6.48–6.53
technical solution 6.06–6.14
Song Zhi’an v Wuxi Furnace Factory (Jiangsu High People’s Court) 16.32–16.33
SSNIP test (small but significant non-transitory increase in price) 17.27
standard-essential patents (SEPs), and injunctive relief 18.01–18.63
European perspective 18.61–18.63
FRAND commitment, legal ambiguity of 18.06–18.15
FRAND statements, interpretation of 18.16–18.41
injunctive relief under Patent Act 18.42–18.48
SEP holder liability, under AML 18.49–18.56
standard-setting organizations (SSOs) 18.03, 18.06
see also standard-essential patents (SEPs), and injunctive relief
State Administration of Industry and Commerce (SAIC) 17.11–17.12
on abuse of dominant market position 17.48–17.57
on abuse of IP rights 17.63
enforcement 17.87, 17.92
essential facilities doctrine 18.55
on FRAND statements 18.52
on horizontal monopoly agreements 17.28–17.38
provincial AICs 17.94
State Council 12.19, 13.06, 16.08, 17.04
adoption of NIPS 1.04
Anti-Monopoly Commission and 17.10
draft regulations 7.03, 17.09
merger control provisions 17.07
special campaign against IPR infringements 12.42
see also State Intellectual Property Office (SIPO)
SSNIP test (small but significant non-transitory increase in price) 8.18–8.19
IP Five Year Plan 12.03, 12.22
mediation option 1.34
National Patent Development Strategy 1.06, 1.20
Notification of Acceptance 9.03
Notification of Passing Preliminary Examination 9.16
patent statistics 1.21, 1.22, 1.28–1.29, 19.04, 20.03
postponed enforcement proposed provisions (2012) 1.19
prioritisation of technology patents 1.23
Provisions of Service Inventions (Draft Provisions) 7.03
re-examination requests, increases in 9.39
website 9.90–9.91
see also Patent Reexamination Board (PRB); individual aspects of application process
state secrets 3.18
State Technological Award 1.32
state-owned enterprises 1.34, 2.50, 17.20
Statistical Yearbook 12.48
staying proceedings see suspension of infringement procedure, suspension of SIPO procedure
straw men 9.50
structural features 15.40, 19.08, 19.10
subsidies 1.25, 1.30, 1.32, 2.40–2.41

467

Stefan Luginbuehl and Peter Ganea - 9781781954843
Downloaded from Elgar Online at 04/24/2019 09:47:00PM via free access
INDEX

superfluous definition doctrine 15.23
Supplementary Protection Certificates 8.53
supply substitutability 17.27
Supreme People’s Court (SPC) 8.53, 12.08, 12.12
on employee invention dispute resolution 7.46–7.47
FRAND statements, interpretation of 18.37–18.41
on infringement damages 13.65
on infringement remedies 13.77
jurisdiction of 13.79, 13.98, 15.01
on post-grant amendments 10.25
on preliminary injunctions 13.130, 14.33–14.34
on preservation of evidence 13.138
Provisions on patent infringement 13.08
status of decisions 8.06, 13.06
see also individual cases
Chinese Civil Procedural Law on 14.11
within defence period 14.17
evaluation reports 14.16
international parallel proceedings 14.26
settlement negotiations and 14.30
time schedules of 14.17, 14.22–14.25
suspension of SIPO procedure 9.83–9.84
Swiss-type claims 4.32–4.39
Taiwan see Chinese Taipei (Taiwan), patent system
Taiwan Fair Trade Act (TFTA) 21.46, 21.49–21.50
Taiyo Yuden 21.51, 21.53–21.55
Tanashin Denki Co Ltd v King Long Industrial Ltd (HKC) 22.54
technical field 3.38, 6.37, 9.26, 15.21, 19.16
technical means and technical features, in software-related inventions 6.41–6.47
technical problems, in software-related inventions 6.48–6.53
technical solution
claim interpretation 15.22–15.26
confidentiality examination 3.19, 11.12
industrial applicability 4.08, 4.12–4.13
patentability 3.01–3.02, 9.28
scientific discoveries 3.07, 4.21
software-related inventions 6.06–6.14
technology transfer 2.01–2.62
best practices 2.47–2.61
contractual restrictions 2.24–2.35
definition 2.01–2.07
history of policies 2.44
imports and exports 2.14–2.23
legal sources 2.08–2.13
political aspects of 2.36–2.46
temporary transit 8.37–8.40
third-party observations 9.29–9.30
three-steps approach (inventive step) 3.38
tie-in sales 17.51
trade associations 17.18, 17.90
trade secret 2.49, 2.57–2.58, 8.30, 9.88
trading counterparties, treatment of 17.52
translation of foreign documents
accuracy of 2.60, 9.04
evidence 13.43
invalidation procedures 9.59–9.60
PCT-CN applications 9.04, 10.06, 10.29–10.36, 21.22
treatment methods see medical treatment methods
Treaty of the Functioning of the European Union (TFEU) 18.62
TRIPs Agreement 1.08, 1.16, 2.36
border measures 21.45
data exclusivity 4.92
exhaustion of rights 16.06, 21.14
infringement 8.01
new products and burden of proof 16.17–16.19
product directly obtained from patented process 16.22
trade secret protection 2.57–2.58
United Kingdom, patent system 19.02, 21.17, 21.27, 22.02–22.06

468
Stefan Lugibuehl and Peter Ganea - 9781781954843
Downloaded from Elgar Online at 04/24/2019 09:47:00PM
via free access
simultaneous application for patent and 1.12, 9.14, 19.24–19.27
statistics 1.28, 2.40–2.41
subject matter of protection 19.08–19.12
validity 12.25

see also invalidation procedure (PRB), infringement and invalidity proceedings
venue, choice of 13.18
vertical agreements 17.39–17.42
warning letters 13.73, 14.53, 21.46, 21.49–21.52

see also declarations of non-infringement

wholly foreign-owned enterprise (WFOE) 2.13

Windsurfing International Inc. v Tabur Marine (Great Britain) Limited (RPC) 22.54

Wing Yick Bamboo Scaffolders Ltd v Wui Loong Scaffolding Works Co Ltd (HKLRD) 22.26

Wuhan Jingyuan Engineering Co. Ltd (Wuhan Jingyuan) v Huayang Electric Industry C. Ltd (Huayang Electric) and Fuji Water Co., Ltd. (Fuji Water) (SPC) 13.54–13.58, 13.129, 18.45

Xiao Zongli v Longyan City Wanteng Vehicle Manufacturing Co et al (Fuzhou Intermediate People’s Court) 8.31

Zhao et al v Patent Reexamination and Adjudication Board (SPC) 3.38
Zhongyu Co. v Jiuying Co. (SPC) 15.28–15.30, 15.32

see also Hong Kong SAR, patent system
United States, patent system 4.90, 15.43, 17.75, 21.35
academic institution applicants 8.51
commercial purpose test and university research 8.44
injunctive relief 18.43
language requirements for documents 2.60
PCT applications 10.38
post-filing of experimental data 4.49, 4.80
PPH bilateral programmes 21.24
recycling 16.08
SEP infringement lawsuits in 18.04
utility model protection, lack of 19.02
viewpoint on Chinese technology transfer regulations 2.36

United States Supreme Court cases 6.19–6.20, 13.57, 16.13, 18.44
unity 9.26, 10.39–10.40
university inventions 7.34–7.36
university research 8.44, 8.51
utility models 19.01–19.33
administrative infringement procedures 12.25
choice of 2.53–2.54, 19.07
commercial use of 19.28–19.32
definition 3.01
evaluation report 14.63
exclusions from protection 19.09
inspection of application files 9.85–9.90
inventiveness and 3.36–3.38, 19.15–19.17
patentability requirements 19.13–19.17
PCT-CN applications and 10.04–10.05, 19.26–19.27
preliminary injunctions 13.127
prosecution and 19.18–19.23
quality issues 1.30

INDEX